Clinical Trial Update: Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses [Phase 2]

View source ↗

Summary

Phase 2 open-label study assessing safety, microbiology, and pharmacokinetics of C16G2 gel doses for dental caries has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dental Caries

Drugs mentioned

• C16G2 gel (C16G2)

Snippet

Sponsor: Armata Pharmaceuticals, Inc. | Conditions: Dental Caries | Phase 2 | Status: COMPLETED